...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024

It is surprising that Zenith is only going for an Equity Private Placement valued at $8M US.

Min subscription of $50K US to institutional and accredited investors.

The price per unit is 60 cents US with a 2-year warrant at 75 cents US.

As I understand it this adds 13.333 Million common shares to ZCC. The Proceeds for continuing oncology clinical development and for RVX apabatelone commercializing efforts. 

 

Koo

 

Share
New Message
Please login to post a reply